Genomic analysis and antimicrobial activity of β-lactam/β-lactamase inhibitors and other agents against KPC-producing Klebsiella pneumoniae clinical isolates from Brazilian hospitals

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorInstituto Adolfo Lutz-
Autor(es): dc.contributorUniversidade de São Paulo (USP)-
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.creatorCamargo, Carlos Henrique-
Autor(es): dc.creatorYamada, Amanda Yaeko-
Autor(es): dc.creatorde Souza, Andreia Rodrigues-
Autor(es): dc.creatorCunha, Marcos Paulo Vieira-
Autor(es): dc.creatorFerraro, Pedro Smith Pereira-
Autor(es): dc.creatorSacchi, Claudio Tavares-
Autor(es): dc.creatordos Santos, Marlon Benedito-
Autor(es): dc.creatorCampos, Karoline Rodrigues-
Autor(es): dc.creatorTiba-Casas, Monique Ribeiro-
Autor(es): dc.creatorFreire, Maristela Pinheiro-
Autor(es): dc.creatorBarretti, Pasqual-
Data de aceite: dc.date.accessioned2025-08-21T22:47:30Z-
Data de disponibilização: dc.date.available2025-08-21T22:47:30Z-
Data de envio: dc.date.issued2025-04-29-
Data de envio: dc.date.issued2023-11-30-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1038/s41598-023-41903-x-
Fonte completa do material: dc.identifierhttps://hdl.handle.net/11449/298024-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/298024-
Descrição: dc.descriptionCarbapenem-resistant Klebsiella pneumoniae (CRKP) are highly disseminated worldwide, and isolates co-resistant to other antimicrobial agents pose a threat to effective antimicrobial therapy. Therefore, evaluation of novel antimicrobial drugs is needed to identify potential treatments with better outcomes. We evaluated the in vitro activity of novel antimicrobial drugs/combinations against 97 KPC-producing Klebsiella pneumoniae isolates recovered from different hospitals in Brazil during 2021–2022. Clonality, resistance and virulence genes were detected by whole-genome sequencing. The majority of the isolates (54.6%) were classified as extensively drug resistant or multidrug resistant (44.3%); one isolate showed a pandrug resistance phenotype. The most active antimicrobial agents were meropenem-vaborbactam, cefiderocol, and ceftazidime-avibactam, with sensitivities higher than 90%; resistance to ceftazidime-avibactam was associated with KPC-33 or KPC-44 variants. Colistin and polymyxin B were active against 58.6% of the isolates. The 97 isolates were distributed into 17 different sequence types, with a predominance of ST11 (37.4%). Although high in vitro susceptibility rates were detected for meropenem-vaborbactam and cefiderocol, only ceftazidime-avibactam is currently available in Brazil. Our findings showed limited susceptibility to antimicrobial drugs employed for infection treatment of carbapenem-resistant K. pneumoniae, underscoring the urgent need for stringent policies for antimicrobial stewardship to preserve the activity of such drugs.-
Descrição: dc.descriptionCentro de Bacteriologia Instituto Adolfo Lutz, Avenida Dr. Arnaldo 351, 9º Andar, SP-
Descrição: dc.descriptionFaculdade de Medicina Universidade de São Paulo, Avenida Dr. Arnaldo 455-
Descrição: dc.descriptionLaboratório Estratégico Instituto Adolfo Lutz, Avenida Dr. Arnaldo 351, 10º Andar-
Descrição: dc.descriptionFaculdade de Medicina de Botucatu Universidade Estadual Paulista, Av. Prof. Montenegro, S/N-
Descrição: dc.descriptionFaculdade de Medicina de Botucatu Universidade Estadual Paulista, Av. Prof. Montenegro, S/N-
Idioma: dc.languageen-
Relação: dc.relationScientific Reports-
???dc.source???: dc.sourceScopus-
Título: dc.titleGenomic analysis and antimicrobial activity of β-lactam/β-lactamase inhibitors and other agents against KPC-producing Klebsiella pneumoniae clinical isolates from Brazilian hospitals-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.